Associated Papers
Pharmacogenomics and mutation informatics: correlation of NAT2 mutations and isoniazid acetylation rate.
Verma S et al.
Drug Discovery Today, 2026
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review.
Hein DW et al.
Expert Opinion on Drug Metabolism & Toxicology, 2021
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.
Yuliwulandari R et al.
Journal of Human Genetics, 2016
Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project.
Pratt VM et al.
The Journal of Molecular Diagnostics : Jmd, 2016
Polymorphism p.Val231Ile alters substrate selectivity of drug-metabolizing arylamine N-acetyltransferase 2 (NAT2) isoenzyme of rhesus macaque and human.
Tsirka T et al.
Gene, 2014
Structural and biochemical characterization of an active arylamine N-acetyltransferase possessing a non-canonical Cys-His-Glu catalytic triad.
Kubiak X et al.
The Journal of Biological Chemistry, 2013
N-Acetyltransferase-2 (NAT2) gene polymorphisms and enzyme activity in Serbs: unprecedented high prevalence of rapid acetylators in a White population.
Djordjevic N et al.
Journal of Clinical Pharmacology, 2011
Effects of single nucleotide polymorphisms on human N-acetyltransferase 2 structure and dynamics by molecular dynamics simulation.
Rajasekaran M et al.
Plos One, 2011
Sequence analysis of NAT2 gene in Brazilians: identification of undescribed single nucleotide polymorphisms and molecular modeling of the N-acetyltransferase 2 protein structure.
Teixeira RL et al.
Mutation Research, 2010
Comparison of genetic polymorphisms of the NAT2 gene between Korean and four other ethnic groups.
Kang TS et al.
Journal of Clinical Pharmacy and Therapeutics, 2009
N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine.
Hein DW
Expert Opinion on Drug Metabolism & Toxicology, 2009
Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity.
Walker K et al.
Journal of Toxicology and Environmental Health. Part B, Critical Reviews, 2009
Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2.
Walraven JM et al.
Current Drug Metabolism, 2008
Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases.
Wu H et al.
The Journal of Biological Chemistry, 2007
Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2.
Zang Y et al.
Carcinogenesis, 2007
Functional characterization of the A411T (L137F) and G364A (D122N) genetic polymorphisms in human N-acetyltransferase 2.
Zang Y et al.
Pharmacogenetics and Genomics, 2007
N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk.
Hein DW
Oncogene, 2006
TaqMan real time-polymerase chain reaction methods for determination of nucleotide polymorphisms in human N-acetyltransferase-1 (NAT1) and -2 (NAT2).
Hein DW et al.
Current Protocols in Toxicology, 2005